Expanded Access to Cemiplimab for Patients with Solid Tumors

Program Overview

This program is designed to offer cemiplimab, a medication for treating solid tumors, to patients who are unable to join clinical trials. This is done through a process called 'expanded access' or 'compassionate use,' which allows patients to receive investigational drugs outside of clinical trials. The availability of cemiplimab through this program depends on where you live and requires an Individual Patient Investigational New Drug (IND) application.

Description

Cemiplimab is being made available to patients with solid tumors who cannot participate in clinical trials through a special program called expanded access. This program is also known as compassionate use and is intended for patients who have no other treatment options. To access cemiplimab, a healthcare provider must submit an Individual Patient Investigational New Drug (IND) application on behalf of the patient. The availability of cemiplimab through this program may vary depending on the patient's location. This program is specifically for patients who need access to cemiplimab but cannot join a clinical trial for various reasons.

Eligibility Criteria